In ₹ Crore except Per Share Latest Annual	TORNTPHARM FY26	SUNPHARMA FY26	JBCHEPHARM FY26	MANKIND FY26	Peer Average
Valuation — at last close
P/E	71.29×	◆ 36.77×	—	53.72×	45.24× +58%
P/B	18.39×	◆ 5.05×	—	6.31×	5.68× +224%
EV/EBITDA	38.65×	◆ 22.19×	—	29.67×	25.93× +49%
Market Cap	₹1.54L Cr	₹4.22L Cr	—	₹1.03L Cr	₹2.62L Cr -41%
Growth
Revenue CAGR 3Y	13.27%	10.03%	9.61%	◆ 17.73%	12.46% +7%
Revenue CAGR 5Y	11.80%	11.78%	◆ 15.22%	—	13.50% -13%
Net Income CAGR 3Y	19.75%	10.57%	◆ 20.06%	13.96%	14.86% +33%
Revenue YoY (latest Q)	◆ 50.79%	10.46%	-4.77%	17.33%	7.67% +562%
Net Income YoY (latest Q)	-9.64%	26.53%	-30.42%	◆ 37.67%	11.26% -186%
Profitability
EBITDA Margin	◆ 32.61%	30.33%	26.70%	25.34%	27.46% +19%
Net Income Margin	15.29%	◆ 19.69%	17.10%	13.57%	16.79% -9%
Return on Common Equity	◆ 27.07%	14.74%	18.69%	12.49%	15.31% +77%
Return on Capital Employed	14.88%	18.48%	◆ 23.07%	12.51%	18.02% -17%
Return on Assets	7.21%	11.46%	◆ 15.35%	6.94%	11.25% -36%
Credit & Quality
Total Debt/Equity	0.84×	0.05×	◆ 0.00×	0.38×	0.14× +486%
Interest Coverage	8.94×	43.65×	◆ 166.06×	4.27×	71.33× -87%
Scale — latest FY
Revenue / Total Income	₹13,980 Cr	₹58,462 Cr	₹4,148 Cr	₹14,278 Cr	₹25,629 Cr -45%
Net Income	₹2,138 Cr	₹11,509 Cr	₹709 Cr	₹1,938 Cr	₹4,719 Cr -55%
Total Assets	₹44,312 Cr	₹1.09L Cr	₹4,969 Cr	₹28,080 Cr	₹47,278 Cr -6%
EPS	₹63.92	₹47.8	₹45.16	₹46.35	₹46.44 +38%
Book Value per Share	₹247.86	₹348.31	₹258.98	₹394.87	₹334.05 -26%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.